Disc Medicine holder may sell 759 shares

Atlas Venture Opportunity Fund II filed a Rule 144 notice to potentially sell 759 shares of Disc Medicine common stock originally acquired in a 2020 private placement.

Rhea-AI Filing Summary

Disc Medicine, Inc. (IRON) has a notice of proposed sale under Rule 144 filed on behalf of Atlas Venture Opportunity Fund II for up to 759 shares of common stock. The shares were originally acquired from the issuer in a private placement on May 1, 2020 for cash.

The filing lists an aggregate market value of $60,241.83 for the shares covered by this notice and references 38,392,844 shares of common stock outstanding as of September 4, 2026 as contextual share information.

Key Figures

Shares to be sold under Rule 144: 759 shares Aggregate market value of shares: $60,241.83 Shares outstanding: 38,392,844 shares +2 more

5 metrics

Shares to be sold under Rule 144 759 shares Maximum common shares covered by the notice for Atlas Venture Opportunity Fund II

Aggregate market value of shares $60,241.83 Value associated with the 759 shares in the securities information section

Shares outstanding 38,392,844 shares Common stock outstanding as of September 4, 2026, given as context

Acquisition date of shares May 1, 2020 Original acquisition date of the 759 shares in a private placement for cash

Date of notice September 4, 2026 Filing date of the Rule 144 notice

Key Terms

Rule 144, Private Placement, Form 144

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Private Placement financial

"Common Stock | 05/01/2020 | Private Placement | Issuer"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

Form 144 regulatory

"144: Issuer Information Name of Issuer | Disc Medicine, Inc."

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

What does the Form 144 filing mean for Disc Medicine, Inc. (IRON)?

The filing reports that Atlas Venture Opportunity Fund II may sell up to 759 shares of Disc Medicine common stock under Rule 144, originally acquired in a May 1, 2020 private placement for cash. It is a notice of potential resale, not an issuance of new shares.

How many IRON shares are covered by this Rule 144 notice?

The notice covers up to 759 shares of common stock of Disc Medicine, Inc. The filing also lists an aggregate market value of $60,241.83 for these shares in the securities information section.

Who is selling the Disc Medicine (IRON) shares under this Form 144?

The person for whose account the securities are to be sold is Atlas Venture Opportunity Fund II. The form states that information is provided for this person and others whose sales must be aggregated under Rule 144 paragraph (e).

When and how were the IRON shares originally acquired?

The 759 shares of Disc Medicine common stock were acquired on May 1, 2020 in a private placement directly from the issuer, with the consideration specified as cash in the securities-to-be-sold section.

What share count context is given for Disc Medicine (IRON) in this filing?

The securities information section lists 38,392,844 shares of common stock outstanding as of September 4, 2026. This figure provides context for the company’s share base relative to the 759 shares covered by the notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:37 PM Accepted by SEC EDGAR 09/04/2026 - 04:35 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001885327
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Disc Medicine, Inc.
SEC File Number	001-39438
Address of Issuer	321 ARSENAL STREET, SUITE 101 WATERTOWN MASSACHUSETTS 02472
Phone	617-674-9274
Name of Person for Whose Account the Securities are To Be Sold	Atlas Venture Opportunity Fund II, LP
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Shareholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch One Bryant Park New York NY 10036	759	60241.83	38392844	09/04/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/01/2020	Private Placement	Issuer			759	05/01/2020	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	See attached Table II for sales of securities over the last three months.
Date of Notice	09/04/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Ommer Chohan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)